ABSTRACT
The dopamine transporter has a crucial role in regulation of dopaminergic neurotransmission by uptake of dopamine into neurons and contributes to the abuse potential of psychomotor stimulants1-3. Despite decades of study, the structure, substrate binding, conformational transitions and drug-binding poses of human dopamine transporter remain unknown. Here we report structures of the human dopamine transporter in its apo state, and in complex with the substrate dopamine, the attention deficit hyperactivity disorder drug methylphenidate, and the dopamine-uptake inhibitors GBR12909 and benztropine. The dopamine-bound structure in the occluded state precisely illustrates the binding position of dopamine and associated ions. The structures bound to drugs are captured in outward-facing or inward-facing states, illuminating distinct binding modes and conformational transitions during substrate transport. Unlike the outward-facing state, which is stabilized by cocaine, GBR12909 and benztropine stabilize the dopamine transporter in the inward-facing state, revealing previously unseen drug-binding poses and providing insights into how they counteract the effects of cocaine. This study establishes a framework for understanding the functioning of the human dopamine transporter and developing therapeutic interventions for dopamine transporter-related disorders and cocaine addiction.
Subject(s)
Benztropine , Dopamine Plasma Membrane Transport Proteins , Dopamine Uptake Inhibitors , Dopamine , Methylphenidate , Models, Molecular , Piperazines , Humans , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Plasma Membrane Transport Proteins/chemistry , Dopamine/metabolism , Methylphenidate/pharmacology , Methylphenidate/metabolism , Methylphenidate/chemistry , Dopamine Uptake Inhibitors/pharmacology , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/chemistry , Piperazines/pharmacology , Piperazines/metabolism , Piperazines/chemistry , Benztropine/pharmacology , Benztropine/metabolism , Benztropine/chemistry , Binding Sites , Protein Binding , Apoproteins/metabolism , Apoproteins/chemistry , Cocaine/pharmacology , Cocaine/metabolism , Protein ConformationABSTRACT
As well known, cocaine induces stimulant effects and dopamine transporter (DAT) trafficking to the plasma membrane of dopaminergic neurons. In the present study, we examined cocaine-induced hyperactivity along with cocaine-induced DAT trafficking and the recovery rate of the dopaminergic system in female rats in comparison with male rats, demonstrating interesting gender differences. Female rats are initially more sensitive to cocaine than male rats in terms of both the DAT trafficking and hyperactivity induced by cocaine. Particularly, intraperitoneal (i.p.) administration of 5 mg/kg cocaine induced significant hyperactivity and DAT trafficking in female rats but not in male rats. After repeated cocaine exposures (i.e., i.p. administration of 20 mg/kg cocaine every other day from Day 0 to Day 32), cocaine-induced hyperactivity in female rats gradually became a clear pattern of two phases, with the first phase of the hyperactivity lasting for only a few minutes and the second phase lasting for over an hour beginning at ~30 min, which is clearly different from that of male rats. It has also been demonstrated that the striatal DAT distribution of female rats may recover faster than that of male rats after multiple cocaine exposures. Nevertheless, despite the remarkable gender differences, our recently developed long-acting cocaine hydrolase, known as CocH5-Fc(M6), can similarly and effectively block cocaine-induced DAT trafficking and hyperactivity in both male and female rats.
Subject(s)
Cocaine , Dopamine Plasma Membrane Transport Proteins , Male , Female , Rats , Animals , Dopamine Plasma Membrane Transport Proteins/metabolism , Cocaine/pharmacology , Cocaine/metabolism , Sex Factors , Dopamine Uptake Inhibitors/pharmacology , Dopamine Uptake Inhibitors/metabolism , Cell Membrane/metabolismABSTRACT
RATIONALE: Drugs that rapidly increase dopamine levels have an increased risk of abuse. Dasotraline (DAS) is a dopamine and norepinephrine reuptake inhibitor characterized by slow oral absorption with low potential for abuse. However, it remains unclear whether intravenous (i.v.) administration would facilitate the rapid elevation of dopamine levels associated with stimulant drugs. OBJECTIVE: To assess the kinetics of DAS across the blood-brain barrier and time to onset of dopamine transporters (DAT) inhibition. METHODS: We compared the onset of DAT occupancy and the associated elevation of synaptic dopamine levels in rhesus monkey following i.v. administration of DAS or methylphenidate (MPH) using positron emission tomography (PET). Brain entry times were estimated by reductions in [18F]-FE-PE2I binding to DAT in rhesus monkeys. Elevations of synaptic dopamine were estimated by reductions in [11C]-Raclopride binding to D2 receptors. RESULTS: Intravenous administration of DAS (0.1 and 0.2 mg/kg) resulted in striatal DAT occupancies of 54% and 68%, respectively; i.v. administered MPH (0.1 and 0.5 mg/kg) achieved occupancies of 69% and 88% respectively. Brain entry times of DAS (22 and 15 min, respectively) were longer than for MPH (3 and 2 min). Elevations in synaptic dopamine were similar for both DAS and MPH however the time for half-maximal displacement by MPH (t = 23 min) was 4-fold more rapid than for DAS (t = 88 min). CONCLUSIONS: These results demonstrate that the pharmacodynamics effects of DAS on DAT occupancy and synaptic dopamine levels are more gradual in onset than those of MPH even with i.v. administration that is favored by recreational drug abusers.
Subject(s)
1-Naphthylamine/analogs & derivatives , Brain/drug effects , Brain/metabolism , Dopamine/metabolism , 1-Naphthylamine/administration & dosage , 1-Naphthylamine/metabolism , Administration, Intravenous , Animals , Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/administration & dosage , Dopamine Uptake Inhibitors/metabolism , Female , Macaca mulatta , Male , Methylphenidate/administration & dosage , Methylphenidate/metabolism , Positron-Emission Tomography/methods , Receptors, Dopamine D2/metabolismABSTRACT
Bupropion, a Food and Drug Administration-approved antidepressant and smoking cessation aid, blocks dopamine and norepinephrine reuptake transporters and noncompetitively inhibits nicotinic acetylcholine and serotonin (5-HT) type 3A receptors (5-HT3ARs). 5-HT3 receptors are pentameric ligand-gated ion channels that regulate synaptic activity in the central and peripheral nervous system, presynaptically and postsynaptically. In the present study, we examined and compared the effect of bupropion and its active metabolite hydroxybupropion on mouse homomeric 5-HT3A and heteromeric 5-HT3AB receptors expressed in Xenopus laevis oocytes using two-electrode voltage clamp experiments. Coapplication of bupropion or hydroxybupropion with 5-HT dose dependently inhibited 5-HT-induced currents in heteromeric 5-HT type 3AB receptors (5-HT3ABRs) (IC50 = 840 and 526 µM, respectively). The corresponding IC50s for bupropion and hydroxybupropion for homomeric 5-HT3ARs were 10- and 5-fold lower, respectively (87 and 113 µM). The inhibition of 5-HT3ARs and 5-HT3ABRs was non-use dependent and voltage independent, suggesting bupropion is not an open channel blocker. The inhibition by bupropion was reversible and time-dependent. Of note, preincubation with a low concentration of bupropion that mimics therapeutic drug conditions inhibits 5-HT-induced currents in 5-HT3A and 5-HT3AB receptors considerably. In summary, we demonstrate that bupropion inhibits heteromeric 5-HT3ABRs as well as homomeric 5-HT3ARs. This inhibition occurs at clinically relevant concentrations and may contribute to bupropion's clinical effects. SIGNIFICANCE STATEMENT: Clinical studies indicate that antagonizing serotonin (5-HT) type 3AB (5-HT3AB) receptors in brain areas involved in mood regulation is successful in treating mood and anxiety disorders. Previously, bupropion was shown to be an antagonist at homopentameric 5-HT type 3A receptors. The present work provides novel insights into the pharmacological effects that bupropion exerts on heteromeric 5-HT3AB receptors, in particular when constantly present at low, clinically attainable concentrations. The results advance the knowledge on the clinical effects of bupropion as an antidepressant.
Subject(s)
Bupropion/metabolism , Bupropion/pharmacology , Receptors, Serotonin, 5-HT3/metabolism , Serotonin 5-HT3 Receptor Antagonists/metabolism , Serotonin 5-HT3 Receptor Antagonists/pharmacology , Amino Acid Sequence , Animals , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Dose-Response Relationship, Drug , Female , Mice , Receptors, Serotonin, 5-HT3/genetics , Stereoisomerism , Xenopus laevisABSTRACT
Atypical dopamine reuptake inhibitors, such as modafinil, are used for the treatment of sleeping disorders and investigated as potential therapeutics against cocaine addiction and for cognitive enhancement. Our continuous effort to find modafinil analogues with higher inhibitory activity on and selectivity toward the dopamine transporter (DAT) has previously led to the promising thiazole-containing derivatives CE-103, CE-111, CE-123, and CE-125. Here, we describe the synthesis and activity of a series of compounds based on these scaffolds, which resulted in several new selective DAT inhibitors and gave valuable insights into the structure-activity relationships. Introduction of the second chiral center and subsequent chiral separations provided all four stereoisomers, whereby the S-configuration on both generally exerted the highest activity and selectivity on DAT. The representative compound of this series was further characterized by in silico, in vitro, and in vivo studies that have demonstrated both safety and efficacy profile of this compound class.
Subject(s)
Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Uptake Inhibitors/pharmacology , Modafinil/analogs & derivatives , Modafinil/pharmacology , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology , Thiazoles/pharmacology , Animals , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/chemical synthesis , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacokinetics , HEK293 Cells , Humans , Male , Modafinil/metabolism , Modafinil/pharmacokinetics , Molecular Docking Simulation , Molecular Structure , Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors , Protein Binding , Rats, Sprague-Dawley , Serotonin Plasma Membrane Transport Proteins/metabolism , Serotonin and Noradrenaline Reuptake Inhibitors/chemical synthesis , Serotonin and Noradrenaline Reuptake Inhibitors/metabolism , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics , Stereoisomerism , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/metabolism , Thiazoles/pharmacokineticsABSTRACT
RATIONALE: The N-phenylpropyl-N'-substituted piperazines SA-4503 (N-phenylpropyl-N'-(3,4-dimethoxyphenethyl)piperazine) and YZ-185 (N-phenylpropyl-N'-(3-methoxyphenethyl)piperazine) bind to sigma (σ) receptors and block the development of cocaine-induced conditioned place preference at concentrations that inhibit cocaine-induced hyperactivity. YZ-067 (N-phenylpropyl-N'-(4-methoxyphenethyl)piperazine) also binds to sigma receptors and attenuates cocaine-induced hyperactivity in mice. OBJECTIVES: The present study determined the effect of YZ-067 on the development and expression of cocaine (66 µmol/kg or 33 µmol/kg) conditioned place preference (CPP) and locomotor sensitization in mice. RESULTS: YZ-067 (10 or 31.6 µmol/kg) did not have intrinsic effects on place preference or place aversion. Interestingly, the 31.6 µmol/kg YZ-067 dose enhanced the development of cocaine place preference, while 10 µmol/kg YZ-067 attenuated the development of cocaine-induced locomotor sensitization. However, YZ-067 did not alter the expression of cocaine place preference nor cocaine-induced locomotor sensitization. In follow-up studies, YZ-067 did not affect performance in the zero maze or rotarod, indicating that sigma receptors probed by this ligand do not regulate anxiety-like or coordinated motor skill behaviors, respectively. CONCLUSION: Overall, these results are consistent with previous studies demonstrating a role for sigma receptors in the behavioral effects of cocaine. However, the present findings also indicate that N-phenylpropyl-N'-substituted piperazines do not strictly block cocaine's behavioral effects and that sigma receptor may differentially mediate cocaine-induced hyperactivity and place conditioning.
Subject(s)
Cocaine/metabolism , Conditioning, Psychological/drug effects , Piperazines/metabolism , Receptors, sigma/agonists , Receptors, sigma/metabolism , Reward , Animals , Cocaine/pharmacology , Conditioning, Psychological/physiology , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Dose-Response Relationship, Drug , Male , Mice , Piperazines/chemistry , Piperazines/pharmacology , Protein Binding/drug effects , Protein Binding/physiologyABSTRACT
BACKGROUND: Chronic cocaine users (CU) display reduced peripheral expression of the glucocorticoid receptor gene (NR3C1), which is potentially involved in stress-related psychiatric symptoms frequently occurring in CU. However, it is unknown whether psychiatric symptoms and lower NR3C1 expression are related to each other and whether reduction of drug consumption reverse them. METHOD: At baseline, NR3C1 mRNA expression was measured in 68 recreational CU, 30 dependent CU, and 68 stimulant-naïve controls. Additionally, the Revised Symptom Checklist (SCL-90R) and the Barratt Impulsiveness Scale (BIS) were assessed. At a one-year follow-up, the association between change in NR3C1 expression and psychiatric symptoms was examined in 48 stimulant-naïve controls, 19 CU who increased and 19 CU who decreased their consumption. At both test sessions, cocaine concentrations in hair samples were determined. Mixed-effects models were used to investigate how changes in drug use intensity affect severity of psychiatric symptoms and NR3C1 expression over time. RESULTS: At baseline, recreational and dependent CU displayed elevated impulsivity and considerable symptom burden across most of the SCL-90R subscales. Time-group interaction effects were found for several impulsivity scores, SCL-90R Global Severity Index, Paranoid Thoughts, and Depression subscales as well as for NR3C1 expression. Pairwise comparisons showed that decreasing CU specifically improved in these SCL-90R subscales, while their NR3C1 expression was adapted. Finally, changes in NR3C1 expression were negatively correlated with changes in impulsivity but not SCL-90R scores. CONCLUSION: Our findings suggest that NR3C1 expression changes and some psychiatric symptoms are reversible upon reduction of cocaine intake, thus favouring abstinence-oriented treatment approaches.
Subject(s)
Cocaine-Related Disorders/metabolism , Cocaine-Related Disorders/physiopathology , Cocaine/metabolism , Dopamine Uptake Inhibitors/metabolism , Gene Expression , Impulsive Behavior/physiology , Receptors, Glucocorticoid/metabolism , Adult , Gene Expression/genetics , Hair/metabolism , Humans , Longitudinal Studies , RNA, Messenger/metabolism , Severity of Illness IndexABSTRACT
Epidemiological studies have shown that people who begin experimenting drugs of abuse during adolescence are more likely to develop substance use disorders, and the earliest is the beginning of their use, the greatest is the likelihood to become dependent. Understanding the neurobiological changes increasing adolescent vulnerability to drug use is becoming imperative. Although all neurotransmitter systems undergo relevant developmental changes, dopamine system is of particular interest, given its role in a variety of functions related to reward, motivation, and decision making. Thus, in the present study, we investigated differences in mesolimbic and nigrostriatal dopamine transmission between adolescent (5, 6, 7 weeks of age) and adult rats (10-12 weeks of age), in basal conditions and following drug challenge, by using in vivo brain microdialysis. Although no significant difference between adolescents and adults was observed in dopamine basal levels in the nucleus accumbens (NAc)shell and core, reduced DA levels were found in the dorsolateral striatum (DLS) of early and mid-adolescent rats. Adolescent rats showed greater increase of dopamine in the NAc shell following nicotine (0.4 mg/kg), THC (1.0 mg/kg), and morphine (1.0 mg/kg), in the NAc core following nicotine and morphine, and in the DLS following THC, morphine, and cocaine (10 mg/kg). These results, while adding new insight in the development and functionality of the dopamine system during different stages of adolescence, might provide a neurochemical basis for the greater vulnerability of adolescents to drugs of abuse and for the postulated gateway effect of nicotine and THC toward abuse of other illicit substances.
Subject(s)
Brain/drug effects , Cocaine/pharmacology , Dopamine/metabolism , Dronabinol/pharmacology , Morphine/pharmacology , Nicotine/pharmacology , Age Factors , Analgesics, Opioid/metabolism , Analgesics, Opioid/pharmacology , Animals , Brain/physiopathology , Cocaine/metabolism , Disease Models, Animal , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Dronabinol/metabolism , Ganglionic Stimulants/metabolism , Ganglionic Stimulants/pharmacology , Male , Microdialysis , Morphine/metabolism , Nicotine/metabolism , Nucleus Accumbens/drug effects , Psychotropic Drugs/metabolism , Psychotropic Drugs/pharmacology , Rats , Substance-Related Disorders/metabolism , Substance-Related Disorders/physiopathology , Synaptic Transmission/drug effectsABSTRACT
The disposition of drugs and their metabolites have been extensively described in the literature, based primarily on the analysis of plasma and urine. However, there are more limited data on their disposition in whole blood, which is often the only specimen available in forensic investigations and cases of driving under the influence of drugs. In this study, we have, for the first time, established pharmacokinetic properties of cocaine (COC) and its metabolites from concurrently collected whole blood and plasma samples, following a single 100 mg dose of cocaine hydrochloride administered via nasal insufflation to seven healthy volunteers. The median Cmax of COC and its major metabolites, benzoylecgonine (BZE) and ecgonine methyl ester (EME), were closely related in whole blood and plasma. The median Cmax for COC in plasma was 379.7 ng/mL (347.5-517.7) and 344.24 ng/mL (271.6-583.2) in whole blood. The median Cmax for BZE in plasma was 441.2 ng/mL (393.6-475. and 371.18 ng/mL (371.1-477.3) in whole blood, EME was 105.5 ng/mL (93.6-151.8) in plasma and 135.5 ng/mL (87.8-183) in whole blood. Calculated medians of the whole blood to plasma ratio of COC (0.76), BZE (0.98) and EME (1.02) of approximately 1, strongly suggesting that the erythrocyte cell wall presents no barrier to COC and its metabolites. Furthermore, whole blood and plasma concentrations of COC were strongly correlated (R2 = 0.0914 R = 0.956, p < 0.0001), as was BZE (R2 = 0.0932 R = 0.965, p < 0.0001) and EME (R2 = 0.0964R = 0.928, p < 0.0001). The minor oxidative metabolite norcocaine (NCOC) was detected in both whole blood and plasma at concentrations between 1 and 5 ng/mL within 60-180 minutes, suggesting that NCOC could be indicator of recent COC administration. Data from this study have shown for the first time that COC and its metabolites BZE and EME are evenly distributed between plasma and whole blood following controlled single-dose intranasal COC administration.
Subject(s)
Cocaine/analogs & derivatives , Cocaine/blood , Dopamine Uptake Inhibitors/blood , Administration, Intranasal , Adult , Chromatography, High Pressure Liquid/methods , Cocaine/administration & dosage , Cocaine/metabolism , Dopamine Uptake Inhibitors/administration & dosage , Dopamine Uptake Inhibitors/metabolism , Female , Humans , Limit of Detection , Male , Tandem Mass Spectrometry/methodsABSTRACT
RATIONALE: MDPV (3,4-methylenedioxypyrovalerone) is a synthetic cathinone present in bath salts. It is a powerful psychostimulant and blocker of the dopamine transporter (DAT), like cocaine. It is known that acute exposure to psychostimulants induces rapid changes in DAT function. OBJECTIVES: To investigate the effects of MDPV on DAT function comparing with cocaine. METHODS: Binding of [3H]WIN 35428 was performed on PC 12 cells treated with MDPV and washed. Rat striatal synaptosomes were incubated with MDPV or cocaine (1 µM) for 1 h and [3H]dopamine (DA) uptake was performed. Also, different treatments with MDPV or cocaine were performed in Sprague-Dawley rats to assess locomotor activity and ex vivo [3H]DA uptake. RESULTS: MDPV increased surface [3H]WIN 35428 binding on PC 12 cells. In vitro incubation of synaptosomes with MDPV produced significant increases in Vmax and KM for [3H]DA uptake. In synaptosomes from MDPV- (1.5 mg/kg, s.c.) and cocaine- (30 mg/kg, i.p.) treated rats, there was a significantly higher and more persistent increase in [3H]DA uptake in the case of MDPV than cocaine. Repeated doses of MDPV developed tolerance to this DAT upregulation and 24 h after the 5-day treatment with MDPV, [3H]DA uptake was reduced. However, a challenge with the same drugs after withdrawal recovered the DAT upregulation by both drugs and showed an increased response to MDPV vs the first dose. At the same time, animals were sensitized to the stereotypies induced by both psychostimulants. CONCLUSIONS: MDPV induces a rapid and reversible functional upregulation of DAT more powerfully and lasting than cocaine.
Subject(s)
Benzodioxoles/pharmacology , Cocaine/pharmacology , Dopamine Plasma Membrane Transport Proteins/agonists , Dopamine Plasma Membrane Transport Proteins/biosynthesis , Dopamine Uptake Inhibitors/pharmacology , Pyrrolidines/pharmacology , Animals , Benzodioxoles/metabolism , Central Nervous System Stimulants/metabolism , Central Nervous System Stimulants/pharmacology , Cocaine/analogs & derivatives , Cocaine/metabolism , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Dopamine Uptake Inhibitors/metabolism , Locomotion/drug effects , Locomotion/physiology , Male , PC12 Cells , Protein Binding/physiology , Pyrrolidines/metabolism , Rats , Rats, Sprague-Dawley , Synaptosomes/drug effects , Synaptosomes/metabolism , Synthetic CathinoneABSTRACT
The initiation of psychostimulant sensitization depends on the mesocorticolimbic dopamine (DA) system. Although many cellular adaptations has been reported to be associated with this addictive behavior, the overall influence of these adaptations on the network regulation of DA neurons has not been established. Here, we profile a network-driven slow oscillation (SO) in the firing activity of ventral tegmental area (VTA) putative DA and non-DA neurons and their correlation with locomotor sensitization induced by repeated administration of cocaine. One day after the last cocaine injection, the power of SO (Pso) significantly increased both in DA and non-DA neurons. Interestingly, the Pso in DA neurons was positively correlated, while Pso in non-DA neurons was negatively correlated with the level of locomotor sensitization. On the other hand, the firing rates of DA and non-DA neurons were both elevated, but none exhibited any correlation with the level of sensitization. Fourteen days after the last injection, the Pso of DA neurons dissipated but still positively correlated with the level of sensitization. In contrast, the Pso in non-DA neurons lost correlation with locomotor sensitization. These results suggest that cocaine-induced locomotor sensitization is associated with long-term network adaptation in DA system and that DA and non-DA neurons may corporately facilitate/hamper the initiation of locomotor sensitization.
Subject(s)
Action Potentials , Cocaine/metabolism , Dopamine Uptake Inhibitors/metabolism , Neurons/drug effects , Ventral Tegmental Area/drug effects , Animals , Behavior, Animal , Male , Motor Activity , Rats, Sprague-DawleyABSTRACT
BACKGROUND: Clobenpropit, a potent antagonist/inverse agonist at the histamine H3 receptor (H3R), reduced the cytotoxic action of 6-hydroxydopamine (6-OHDA) in neuroblastoma SH-SY5Y cells transfected with the human H3R. We therefore set out to study whether this effect involved a receptor-independent action on dopamine transport. METHODS: The uptake of [3H]-dopamine was assayed in SH-SY5Y cells and rat striatal or cerebro-cortical isolated nerve terminals (synaptosomes). Clobenpropit binding to the human norepinephrine (NET) and dopamine (DAT) transporters was analyzed by molecular modeling. RESULTS: In SH-SY5Y cells, [3H]-dopamine uptake was inhibited by desipramine (selective NET inhibitor), GBR-12909 (selective DAT inhibitor), and fluoxetine (selective inhibitor of the serotonin transporter, SERT) with IC50 values 37, 537, and 2800nM, respectively. The potency rank order indicates that [3H]-dopamine uptake is primarily performed by NET. Clobenpropit inhibited [3H]-dopamine uptake (maximum inhibition 82.7±2.8%, IC50 490nM), and the effect was reproduced by the H3R antagonist/inverse agonist iodophenpropit, but not by the agonists R-α-methylhistamine and immepip or the antagonists/inverse agonists ciproxifan and A-331440. Clobenpropit also inhibited [3H]-dopamine uptake by rat striatal and cerebro-cortical synaptosomes (-54.6±11.3% and -46.3±9.6%, respectively, at 10µM). Modeling of the human NET and DAT obtained by homology from the crystal of Drosophila melanogaster DAT showed that clobenpropit can bind to a site also recognized in both transporters by nisoxetine, a potent NET inhibitor. CONCLUSION: These data indicate a direct inhibitory effect of clobenpropit on catecholamine transport.
Subject(s)
Brain/drug effects , Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Uptake Inhibitors/pharmacology , Dopamine/metabolism , Histamine H3 Antagonists/pharmacology , Imidazoles/pharmacology , Receptors, Histamine H3/drug effects , Synaptosomes/drug effects , Thiourea/analogs & derivatives , Animals , Binding Sites , Brain/metabolism , Cell Line, Tumor , Dopamine Plasma Membrane Transport Proteins/chemistry , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/chemistry , Dopamine Uptake Inhibitors/metabolism , Dose-Response Relationship, Drug , Drosophila Proteins/antagonists & inhibitors , Drosophila Proteins/metabolism , Drug Inverse Agonism , Histamine H3 Antagonists/chemistry , Histamine H3 Antagonists/metabolism , Humans , Imidazoles/chemistry , Imidazoles/metabolism , Molecular Docking Simulation , Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors , Norepinephrine Plasma Membrane Transport Proteins/metabolism , Protein Binding , Protein Conformation , Rats , Receptors, Histamine H3/metabolism , Synaptosomes/metabolism , Thiourea/chemistry , Thiourea/metabolism , Thiourea/pharmacologyABSTRACT
Although it is universally accepted that dopamine transporters (DATs) exist in monomers, dimers and tetramers (i.e. dimers of dimers), it is not known whether the oligomeric organization of DAT is a prerequisite for its ability to take up dopamine (DA), or whether each DAT protomer, the subunit of quaternary structure, functions independently in terms of DA translocation. In this study, copper phenanthroline (CuP) was used to selectively target surface DAT: increasing concentrations of CuP gradually cross-linked natural DAT dimers in LLC-PK1 cells stably expressing hDAT and thereby reduced DA uptake functionality until all surface DATs were inactivated. DATs that were not cross-linked by CuP showed normal DA uptake with DA Km at ~ 0.5 µM and DA efflux with basal and amphetamine-induced DA efflux as much as control values. The cocaine analog 2ß-carbomethoxy-3ß-[4-fluorophenyl]-tropane (CFT) was capable to bind to copper-cross-linked DATs, albeit with an affinity more than fivefold decreased (Kd of CFT = 109 nM after cross-linking vs 19 nM before). A kinetic analysis is offered describing the changing amounts of dimers and monomers with increasing [CuP], allowing the estimation of dimer functional activity compared with a DAT monomer. Consonant with previous conclusions for serotonin transporter and NET that only one protomer of an oligomer is active at the time, the present data indicated a functional activity of the DAT dimer of 0.74 relative to a monomer.
Subject(s)
Dopamine Plasma Membrane Transport Proteins/chemistry , Dopamine Plasma Membrane Transport Proteins/metabolism , Phenanthrolines/chemistry , Animals , Biotinylation , Cocaine/chemistry , Cocaine/metabolism , Cross-Linking Reagents/chemistry , Dopamine Uptake Inhibitors/chemistry , Dopamine Uptake Inhibitors/metabolism , HEK293 Cells , Humans , Kinetics , LLC-PK1 Cells , Protein Binding , Swine , TropanesABSTRACT
Although hair is widely used to identify drug use, there is a risk of false positives due to environmental contamination. This especially applies to cocaine (COC). Several strategies such as detection of norcocaine (NCOC) or cocaethylene, metabolite concentration ratios or intricate washing procedures have been proposed to differentiate actual use from contamination. The aim of the present study was to identify hydroxy metabolites of COC in hair specimens, thus enabling unambiguous prove of ingestion. A suspect screening of 41 COC-positive samples for these compounds was performed by liquid chromatography-quadrupole time of flight-mass spectrometry (LC-QTOF-MS). Once identified, mass transitions for o-, p- and m-isomers of hydroxy COC as well as p- and m-isomers of hydroxy benzoylecgonine (BE) and hydroxy NCOC were introduced into a routine procedure for testing drugs of abuse in hair by liquid chromatography-tandem mass spectrometry (LC-MS/MS) which was applied to 576 hair samples. Hydroxy metabolites were present in 92.2% of COC-positive hair samples; their detection rate exceeded that of cocaethylene and NCOC. Moreover, p-OH-BE, m-OH-BE as well as p-OH-NCOC and m-OH-NCOC have been identified for the first time in COC-positive hair specimens. Hydroxy cocainics could be detected in samples having a negative conclusion on drug use applying hitherto established criteria. We suggest a more conclusive interpretation outcome including detection of hydroxy metabolites into the evaluation of COC-positive hair samples.
Subject(s)
Cocaine/analysis , Dopamine Uptake Inhibitors/analysis , Hair/chemistry , Illicit Drugs/analysis , Substance Abuse Detection/methods , Cocaine/analogs & derivatives , Cocaine/metabolism , Dopamine Uptake Inhibitors/metabolism , Hair/metabolism , Humans , Hydroxylation , Illicit Drugs/metabolism , Limit of Detection , Tandem Mass Spectrometry/methodsABSTRACT
The dopamine transporter (DAT) controls the spatial and temporal dynamics of dopamine neurotransmission through reuptake of extracellular transmitter and is a target for addictive compounds such as cocaine, amphetamine (AMPH), and methamphetamine (METH). Reuptake is regulated by kinase pathways and drug exposure, allowing for fine-tuning of clearance in response to specific conditions, and here we examine the impact of transporter ligands on DAT residue Thr-53, a proline-directed phosphorylation site previously implicated in AMPH-stimulated efflux mechanisms. Our findings show that Thr-53 phosphorylation is stimulated in a transporter-dependent manner by AMPH and METH in model cells and rat striatal synaptosomes, and in striatum of rats given subcutaneous injection of METH. Rotating disc electrode voltammetry revealed that initial rates of uptake and AMPH-induced efflux were elevated in phosphorylation-null T53A DAT relative to WT and charge-substituted T53D DATs, consistent with functions related to charge or polarity. These effects occurred without alterations of surface transporter levels, and mutants also showed reduced cocaine analog binding affinity that was not rescued by Zn2+ Together these findings support a role for Thr-53 phosphorylation in regulation of transporter kinetic properties that could impact DAT responses to amphetamines and cocaine.
Subject(s)
Amphetamine/pharmacology , Biological Transport/drug effects , Cocaine/metabolism , Dopamine Agents/pharmacology , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/metabolism , Dopamine/metabolism , Animals , Cell Line , Cocaine/analogs & derivatives , Dopamine Uptake Inhibitors/chemistry , Male , Methamphetamine/pharmacology , Phosphorylation/drug effects , Protein Binding/drug effects , Rats, Sprague-Dawley , Swine , Threonine/metabolismABSTRACT
Dopamine transporter (DAT) has been shown to accumulate in filopodia in neurons and non-neuronal cells. To examine the mechanisms of DAT filopodial targeting, we used quantitative live-cell fluorescence microscopy, and compared the effects of the DAT inhibitor cocaine and its fluorescent analog JHC1-64 on the plasma membrane distribution of wild-type DAT and two non-functional DAT mutants, R60A and W63A, that do not accumulate in filopodia. W63A did not bind JHC1-64, whereas R60A did, although less efficiently compared to the wild-type DAT. Molecular dynamics simulations predicted that R60A preferentially assumes an outward-facing (OF) conformation through compensatory intracellular salt bridge formation, which in turn favors binding of cocaine. Imaging analysis showed that JHC1-64-bound R60A mutant predominantly localized in filopodia, whereas free R60A molecules were evenly distributed within the plasma membrane. Cocaine binding significantly increased the density of R60A, but not that of W63A, in filopodia. Further, zinc binding, known to stabilize the OF state, also increased R60A concentration in filopodia. Finally, amphetamine, that is thought to disrupt DAT OF conformation, reduced the concentration of wild-type DAT in filopodia. Altogether, these data indicate that OF conformation is required for the efficient targeting of DAT to, and accumulation in, filopodia.
Subject(s)
Amphetamine/pharmacology , Chlorides/pharmacology , Cocaine/pharmacology , Dextroamphetamine/pharmacology , Dopamine Plasma Membrane Transport Proteins/chemistry , Zinc Compounds/pharmacology , Amphetamine/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cell Line , Chlorides/metabolism , Cocaine/analogs & derivatives , Cocaine/metabolism , Dextroamphetamine/metabolism , Dopamine/metabolism , Dopamine/pharmacology , Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelial Cells/ultrastructure , Gene Expression , Genes, Reporter , HEK293 Cells , Humans , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Molecular Docking Simulation , Mutation , Protein Binding , Protein Conformation , Pseudopodia/drug effects , Pseudopodia/metabolism , Pseudopodia/ultrastructure , Zinc Compounds/metabolismABSTRACT
Behavioral sensitization is a progressive and enduring enhancement of the motor stimulant effects elicited by repeated administration of drugs of abuse. It can be divided into two distinct temporal and anatomical domains, termed initiation and expression, which are characterized by specific molecular and neurochemical changes. This study examines the role of the Wnt canonical pathway mediating the induction of cocaine sensitization. We found that ß-catenin levels in the prefrontal cortex (PFC), amygdala (Amyg) and dorsal striatum (CPu) are decreased in animals that show sensitization. Accordingly, GSK3ß activity levels are increased in the same areas. Moreover, ß-catenin levels in nuclear fraction, mRNA expression of Axin2 and Wnt7b are decreased in the PFC of sensitized animals. Then, in order to demonstrate that changes in the PFC are crucial for initiation of sensitization, we either rescue ß-catenin levels with a systemic treatment of a GSK3ß inhibitor (Lithium Chloride) or inhibit Wnt/ß-catenin pathway with an intracerebral infusion of Sulindac before each cocaine injection. As expected, rescuing ß-catenin levels in the PFC as well as CPu and Amyg blocks cocaine-induced sensitization, while decreasing ß-catenin levels exclusively in the PFC exacerbates it. Therefore, our results demonstrate a new role for the Wnt/ß-catenin pathway as a required neuroadaptation in inducing behavioral sensitization.
Subject(s)
Brain/drug effects , Brain/metabolism , Cocaine/pharmacology , Prefrontal Cortex/metabolism , Wnt Signaling Pathway , Animals , Cocaine/metabolism , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Male , Models, Animal , Rats , Rats, WistarABSTRACT
Recreational drug use leads to compulsive substance abuse in some individuals. Studies on animal models of drug addiction indicate that persistent long-term potentiation (LTP) of excitatory synaptic transmission onto ventral tegmental area (VTA) dopamine (DA) neurons is a critical component of sustained drug seeking. However, little is known about the mechanism regulating such long-lasting changes in synaptic strength. Previously, we identified that translational control by eIF2α phosphorylation (p-eIF2α) regulates cocaine-induced LTP in the VTA (Huang et al., 2016). Here we report that in mice with reduced p-eIF2α-mediated translation, cocaine induces persistent LTP in VTA DA neurons. Moreover, selectively inhibiting eIF2α-mediated translational control with a small molecule ISRIB, or knocking down oligophrenin-1-an mRNA whose translation is controlled by p-eIF2α-in the VTA also prolongs cocaine-induced LTP. This persistent LTP is mediated by the insertion of GluR2-lacking AMPARs. Collectively, our findings suggest that eIF2α-mediated translational control regulates the progression from transient to persistent cocaine-induced LTP.
Subject(s)
Action Potentials/drug effects , Cocaine/metabolism , Dopamine Uptake Inhibitors/metabolism , Dopaminergic Neurons/physiology , Eukaryotic Initiation Factor-2/metabolism , Protein Biosynthesis , Ventral Tegmental Area/physiology , Animals , Dopaminergic Neurons/drug effects , Mice , Ventral Tegmental Area/drug effectsABSTRACT
BACKGROUND: The personality trait of negative urgency, characterized as behaving rashly when emotionally perturbed, is gaining attention as an indicator for susceptibility to problematic substance use. How this trait is influenced by exposure to drugs of abuse is still unclear. Using an animal model of binge cocaine consumption, we tested this relationship in a reward-omission task across multiple days. METHODS: Adult, male, Sprague-Dawley rats received seven daily (ip) injections of saline, cocaine (10-20mg/kg), or cocaine (20-40mg/kg). Cocaine doses increased linearly each day from the lower to the higher dose. A separate group received RTI-113 (3.0mg/kg), a selective dopamine transporter inhibitor, for 7 days. Fifteen days after their final injection, rats were trained on a reward-omission task with an operant component to earn further rewards. RESULTS: Previous exposure to cocaine resulted in dose-dependent increases in negative urgency in separate behavioral variables across days of testing. The lower dose range increased negative urgency on the dimension of decreased reaction time to press a lever, while the higher dose range increased the rate of increase in lever presses made per trial. Rats receiving RTI-113 did not resemble either cocaine group and instead showed a decrease in lever pressing across days. CONCLUSIONS: Our results indicate that previous binge cocaine consumption enhances behavioral markers of negative urgency in a dose-dependent, time-sensitive manner on discrete behavioral dimensions. The results with RTI-113 suggest the relationship between cocaine exposure and negative urgency is unlikely to be explained solely by inhibition of dopamine reuptake.
Subject(s)
Behavior, Addictive/psychology , Cocaine/administration & dosage , Conditioning, Operant/drug effects , Reward , Substance Withdrawal Syndrome/psychology , Animals , Behavior, Addictive/metabolism , Cocaine/analogs & derivatives , Cocaine/metabolism , Cocaine/pharmacology , Conditioning, Operant/physiology , Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/metabolism , Dopamine Uptake Inhibitors/pharmacology , Dose-Response Relationship, Drug , Male , Rats , Rats, Sprague-Dawley , Substance Withdrawal Syndrome/metabolismABSTRACT
BACKGROUND: While the advancement of highly active antiretroviral therapy (HAART) has transformed the course of HIV/AIDS from a death sentence to a manageable chronic condition, the prevalence of a constellation of neurological disorders collectively termed as HIV-associated neurocognitive disorders (HAND) continues to persist in these patients. HAND is characterized by cognitive dysfunction, depression, impaired memory and/or deficits in motor skills. The underlying factors leading to HAND have been the subject of extensive research and are thought to be associated with HIV infection in the CNS combined with robust immune activation of resident cells of the CNS. In addition, there is a strong correlation between chronic substance abuse and the manifestation of HAND. Among the various commonly abused drugs, cocaine has been extensively studied for its ability to exacerbate the neuropathogenesis of HAND. Ample evidence suggests that cocaine not only facilitates viral replication in macrophages and microglia, but also inflicts deleterious effects on various other cells of the CNS, thereby contributing to the potentiation of HAND. Cocaine has been shown to enhance the permeability of the blood-brain barrier (BBB) through various mechanisms including direct pro-apoptotic effects on brain endothelial cells, systemic induction of inflammatory factors which have been demonstrated to down-regulate tight junction proteins and via up-regulation of several endothelial adhesion molecules leading to accelerated breach of the BBB and increased influx of HIV-infected leukocytes into the CNS. Cocaine also enhances viral replication in CNS astrocytes and promotes astrogliosis via astrocyte activation and proliferation. Furthermore, cocaine also exacerbates neuroinflammatory responses by mediating microglial activation and migration. In addition to cellular injury mediated by inflammatory responses, cocaine also directly affects the brain reward system by disrupting the homeostasis of neurotransmitters such as dopamine and acetylcholine and works synergistically with viral proteins such as tat and gp120 to promote neuronal injury. CONCLUSION: This review highlights previous studies in the field on the role of cocaine in the progression of HAND and gives an overview of the major signaling pathways in the CNS that are involved in this process.